John C Vederas

This inventor holds 10 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 3 EPO patents. Top assignees: University of Alberta, The Governors of the Univerity of Alberta, Other. Active years: 1990-2020.

USPTO Granted Patents = 10 (Patent Applications = 1)

% Patents Active = 90.0

CIPO Patents = 3

EPO Patents = 3

Average Co-Inventor Count = 3.1

ph-index = 4

Forward Citations = 43(Granted Patents)

Company Filing History:

8 out of 454

University of Alberta

patents

1 out of 2

The Governors of the Univerity of Alberta

patents

1 out of 834,307

Other

patents

Years Active: 1990-2020

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10723776 - Apelin peptides and uses thereof (2020-07-28),

2. 10640545 - Apelin peptides and uses thereof (2020-05-05),

3. 8202901 - Compounds that stimulate glucose utilization and methods of use (2012-06-19),

4. 7524885 - Compounds that stimulate glucose utilization and methods of use (2009-04-28),

5. 7473706 - Compounds that stimulate glucose utilization and methods of use (2009-01-06),

6. 7084173 - Compounds that stimulate glucose utilization and methods of use (2006-08-01),

7. 7074828 - Compounds that stimulate glucose utilization and methods of use (2006-07-11),

8. 6403082 - Bacteriocins, transport and vector system and method of use thereof (2002-06-11),

9. 5200526 - Syntheses of optically pure .alpha.-amino acids from 3-amino-2-oxetanone (1993-04-06),

10. 4960832 - Polymer-supported alkyl azodicarboxylates and their use in Mitsunobu (1990-10-02),

Title: John C Vederas: Innovator in Apelin Peptides

Introduction

John C Vederas is a prominent inventor based in Edmonton, Canada. He has made significant contributions to the field of biochemistry, particularly in the development of modified apelin polypeptides. With a total of 10 patents to his name, Vederas has established himself as a key figure in innovative research aimed at addressing cardiovascular disorders.

Latest Patents

One of Vederas' latest patents focuses on apelin peptides and their uses. The disclosure relates to modified apelin polypeptides that exhibit increased stability against kallikrein, NEP, and ACE2 degradation. These modified peptides also demonstrate enhanced potency compared to the native apelin-13 and apelin-17 polypeptides. The embodiments of this patent include methods for utilizing these polypeptides in the treatment of cardiovascular disorders, showcasing Vederas' commitment to advancing medical science.

Career Highlights

Throughout his career, John C Vederas has been associated with the University of Alberta, where he has contributed to various research initiatives. His work has not only advanced the understanding of apelin peptides but has also paved the way for potential therapeutic applications in cardiovascular health.

Collaborations

Vederas has collaborated with notable colleagues in his field, including Gary David Lopaschuk and Jason Roland Dyck. These partnerships have further enriched his research and have led to significant advancements in the study of apelin peptides.

Conclusion

John C Vederas is a distinguished inventor whose work on apelin peptides has the potential to transform treatments for cardiovascular disorders. His innovative research and collaborations continue to make a lasting impact in the field of biochemistry.